Stent thrombosis redux - The FDA perspective

New England Journal of Medicine

Volumn 356, Issue 10, 2007, Pages 984-987

  Farb, Andrew ^a   Boam, Ashley B ^a  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

CLINICAL TRIAL; COMORBIDITY; DRUG ELUTING STENT; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TAXUS; THROMBOSIS;

EID: 33847707734     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068304     Document Type: Article

References (5)

1. Muni NI, Gross TP. Problems with drug-eluting coronary stents - the FDA perspective. N Engl J Med 2004;351:1593-5.
2. Camenzind E, Steg PG, Wijns W. A meta-analysis of first generation drug eluting stent programs. Presented at the World Congress of Cardiology 2006, Barcelona, September 2-5, 2006. abstract.
3. Wenaweser P, Tsuchida K, Vaina S, et al. Late stent thrombosis following drug-eluting stent implantation: data from a large, two-institutional cohort study. Presented at the World Congress of Cardiology 2006, Barcelona, September 2-5, 2006. abstract.
4. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2006;297:159-68.
5. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-e121. (Also available at http://www.acc.org/qualityandscience/clinical/guidelines/ percutaneous/update/index.pdf.)